Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Recent-Onset Psychosis and Cannabis Use
NCT03883360Phase 2Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2050
- Primary completion
- Feb 2050
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in schizophrenia spectrum and other psychotic disorders, cannabis use disorder (CUD), sponsored by University of Maryland, Baltimore. Planned start Jan 2050; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
schizophrenia spectrum and other psychotic disorderscannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03883360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883360.